ABVX Abivax S.A. IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1956827 · Reporting currency EUR · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: EUR | 2025Q4*2025-12-31 | 2025Q3*2025-09-30 | 2025Q2*2025-06-30 | 2025Q1*2025-03-31 | 2024Q4*2024-12-31 | 2024Q3*2024-09-30 | 2024Q2*2024-06-30 | 2024Q1*2024-03-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | 44.40M | 55.42M | 38.65M | 39.30M | 38.60M | 43.29M | 28.91M | 35.74M |
| SG&A expense | 25.87M | 25.50M | 8.27M | 8.03M | 7.64M | 7.38M | 9.80M | 8.14M |
| Operating income | -71.65M | -80.71M | -46.50M | -47.20M | -42.80M | -50.19M | -35.33M | -44.67M |
| Interest expense | 9.27M | 93.05M | 5.42M | 6.72M | 364,000 | 8.47M | 7.06M | 4.23M |
| Pretax income | -76.11M | -153.36M | -48.41M | -52.37M | -39.38M | -55.23M | -38.77M | -42.87M |
| Income tax | 5.85M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | -81.96M | -153.36M | -48.41M | -52.37M | -39.38M | -55.23M | -38.77M | -42.87M |
| EBITDA | -71.37M | -80.44M | -46.24M | -46.93M | -42.52M | -49.94M | -34.96M | -44.46M |
| EPS (basic) | — | -2.10 | -0.76 | -0.83 | — | -0.87 | -0.62 | -0.68 |
| EPS (diluted) | — | -2.10 | -0.76 | -0.83 | — | -0.87 | -0.62 | -0.68 |
| Weighted avg. shares (diluted) | — | 72.94M | 63.44M | 63.38M | — | 63.23M | 62.92M | 62.92M |
| Balance sheet | ||||||||
| Cash & equivalents | 516.68M | 589.70M | 60.95M | 103.58M | 144.22M | 180.45M | 222.32M | 241.61M |
| Short-term investments | 0 | 0 | 0 | 0 | 136,000 | — | — | — |
| Current assets | 551.24M | 619.29M | 86.10M | 132.67M | 170.67M | — | — | — |
| PP&E, netmay include right-of-use assets (IFRS) | 2.09M | 1.91M | 2.16M | 2.41M | 2.67M | 2.62M | 2.57M | 686,000 |
| Goodwill | 18.42M | 18.42M | 18.42M | 18.42M | 18.42M | — | — | — |
| Intangibles | 6.61M | 6.61M | 6.61M | 6.61M | 6.61M | 6.61M | 6.61M | 6.60M |
| Total assets | 584.34M | 652.05M | 119.64M | 166.94M | 205.23M | — | — | — |
| Current liabilities | 63.02M | 78.76M | 112.35M | 105.74M | 94.00M | — | — | — |
| Total liabilities | 129.14M | 140.81M | 167.92M | 173.53M | 164.64M | — | — | — |
| Shareholders' equity | 455.20M | 511.24M | -48.28M | -6.59M | 40.58M | 75.88M | 126.47M | 158.87M |
| Shares outstanding | — | — | 63.47M | 63.42M | 63.35M | — | — | — |
| Cash flow statement | ||||||||
| Operating cash flow | -23.23M | -71.28M | -33.34M | -33.28M | -33.51M | -35.38M | -50.42M | -34.75M |
| Capital expenditure | 87,000 | -8,000 | 19,000 | 44,000 | 93,000 | 311,000 | 224,000 | 12,000 |
| Free cash flow | -23.32M | -71.28M | -33.36M | -33.32M | -33.61M | -35.69M | -50.65M | -34.77M |
| Investing cash flow | -12.74M | 3.28M | 187,000 | 1.08M | 556,000 | 1.75M | 11.56M | 1.90M |
| Financing cash flow | -39.55M | 603.46M | -8.77M | -7.84M | -5.83M | -6.29M | 19.12M | 21.20M |
| Depreciation & amortization | 276,000 | 272,000 | 251,000 | 273,000 | 279,000 | 245,000 | 365,000 | 211,000 |
| Stock-based compensation | 12.90M | 11.48M | 6.33M | 4.69M | 4.46M | 4.35M | 5.67M | 5.75M |
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.